Filing Details

Accession Number:
0000880771-16-000177
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-08-16 17:32:06
Reporting Period:
2016-08-12
Filing Date:
2016-08-16
Accepted Time:
2016-08-16 17:32:06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
880771 Sciclone Pharmaceuticals Inc SCLN Pharmaceutical Preparations (2834) 943116852
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1600522 Chuncai Meng 950 Tower Lane, Suite 200
Foster City CA 94404
Gen. Counsel & Vp Compliance No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-08-12 23,333 $4.52 23,333 No 4 M Direct
Common Stock Disposition 2016-08-12 23,333 $10.41 0 No 4 S Direct
Common Stock Acquisiton 2016-08-12 7,000 $8.83 7,000 No 4 M Direct
Common Stock Disposition 2016-08-12 7,000 $10.41 0 No 4 S Direct
Common Stock Acquisiton 2016-08-12 750 $0.00 750 No 4 M Direct
Common Stock Disposition 2016-08-12 750 $10.41 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Options (right to buy) Disposition 2016-08-12 23,333 $0.00 23,333 $4.52
Common Stock Non-Qualified Stock Options (right to buy) Disposition 2016-08-12 7,000 $0.00 7,000 $8.83
Common Stock Restricted Stock Unit Disposition 2016-08-12 750 $0.00 750 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
30,000 2024-03-14 No 4 M Direct
14,000 2025-03-16 No 4 M Direct
5,250 No 4 M Direct
Footnotes
  1. Granted under the Issuer's 2005 Equity Incentive Plan.
  2. 25% of such shares vest on February 9, 2015 and 2.0833% vests each month thereafter provided that the Reporting Person continues to be employed by the Issuer.
  3. 25% of such shares vest from one year from the date of grant and 2.0833% vests each month thereafter, provided that the Reporting Person continues to be employed by the Issuer.
  4. Each restricted stock unit represents the contingent right to receive one share of SciClone Pharmaceuticals, Inc.'s common stock.
  5. Vesting for such RSUs will occur 25% on March 16, 2016, 25% on March 16, 2017, 25% on March 16, 2018, and 25% on March 16, 2019, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment.